Trading Symbol: TSX/NYSE AMERICAN: SVM VANCOUVER, BC , May 22, 2025 /PRNewswire/ - Silvercorp Metals Inc. ("Silvercorp" or the "Company") (TSX: SVM) (NYSE American: SVM) reported its financial and operating results for the three months ("Q4 Fiscal 2025") and twelve months ("Fiscal 2025") ended March 31, 2025. All amounts are expressed in US dollars, and figures may not add due to rounding.

REDWOOD CITY, Calif., May 22, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Soleno's Marketing Authorization Application (MAA) seeking regulatory approval of Diazoxide Choline Prolonged-Release Tablets (previously referred to as DCCR) for the treatment of adults and children four years and older with Prader-Willi syndrome (PWS) who have hyperphagia had been validated by the European Medicines Agency (EMA).

One-time Amtagvi Treatment Demonstrated Durable Responses and a Five-year Overall Survival Rate of 20% Five-year Follow Up is Unprecedented for Any Therapy in Patients with Advanced Melanoma Previously Treated with Immune Checkpoint Inhibitor SAN CARLOS, Calif., May 22, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced five-year results from the Phase 2 C-144-01 clinical trial evaluating the individualized T cell therapy Amtagvi® (lifileucel).

Shares of quantum computing companies rocketed higher Thursday, led by IonQ (IONQ), whose chief executive said it aims to become the Nvidia (NVDA) of quantum computing.

NEW YORK, NY / ACCESS Newswire / May 22, 2025 / If you suffered a loss on your BigBear.ai Holdings, Inc. (NYSE:BBAI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/bigbear-ai-holdings-inc-lawsuit-submission-form?prid=149849&wire=1&utm_campaign=21 or contact Joseph E. Levi, Esq.

NEW YORK, NY / ACCESS Newswire / May 22, 2025 / If you suffered a loss on your Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/iovance-biotherapeutics-inc-lawsuit-submission-form?prid=149850&wire=1&utm_campaign=9 or contact Joseph E. Levi, Esq.

NEW YORK CITY, NY / ACCESS Newswire / May 22, 2025 / WHY: New York, N.Y., May 22, 2025.

MORRISTOWN, N.J. , May 22, 2025 /PRNewswire/ -- Sanofi today announces the formal opening of the company's new flagship US offices, unveiling a state-of-the-art modern workplace fostering collaboration and innovation with the ultimate goal of bringing medicines and vaccines to patients faster.

– Results from KOMET-001 registration-directed trial of ziftomenib in R/R NPM1-m AML patients selected for oral presentation on Monday, June 2nd –

New York, New York, May 22, 2025 (GLOBE NEWSWIRE) -- Univest Securities, LLC (“Univest”), a member of FINRA and SIPC, and a full-service investment bank and securities broker-dealer firm based in New York, today announced the closing of registered offering (the “Offering”) for its client WORK Medical Technology Group LTD (Nasdaq: WOK) (the “Company”), a supplier of medical devices in China, through its subsidiary, Work (Hangzhou) Medical Treatment Equipment Co., Ltd. and its subsidiaries in China.

- 63% response rate observed among 43 evaluable patients - 79% overall survival rate at 12-months; 9 months median progression-free survival - Conference Call on Thursday, May 22 at 5:30 p.m. ET UTRECHT, The Netherlands and CAMBRIDGE, Mass.

NEW YORK , May 22, 2025 /PRNewswire/ -- This press release provides shareholders of Cohen & Steers Infrastructure Fund, Inc. (NYSE: UTF) (the "Fund") with information regarding the sources of the distribution to be paid on May 30, 2025 and cumulative distributions paid fiscal year-to-date. In March 2015, the Fund implemented a managed distribution policy in accordance with exemptive relief issued by the Securities and Exchange Commission.

Phase 2: Versamune ® HPV with pembrolizumab as 1L treatment of r/m HPV16-positive HNSCC

The lawsuit alleged the beverage company provided promotional pricing deals to a single big-box customer but didn't give the same incentives to other retailers.

NEW YORK , May 22, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Digimarc Corporation (NASDAQ: DMRC) between May 3, 2024 and February 26, 2025, both dates inclusive (the "Class Period"), of the important July 8, 2025 lead plaintiff deadline. So what: If you purchased Digimarc securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

Universal Digital and LongPoint enter into a partnership agreement to establish ETFs in Canada Universal Digital and LongPoint have filed a preliminary prospectus seeking to list 2X leveraged single stock ETFs on Coinbase and MicroStrategy Vancouver, British Columbia--(Newsfile Corp. - May 22, 2025) - Universal Digital Inc. (CSE: LFG) (FSE: 8R20) (the "Company" or "Universal Digital") is pleased to announce that it has entered into a partnership with LongPoint Asset Management Inc. ("LongPoint") and filed a preliminary prospectus in connection with the proposed launch of two new leveraged exchange traded funds (the "ETFs"). The proposed LFG Daily (2X) COIN Long …

LAWRENCEVILLE, N.J., May 22, 2025 (GLOBE NEWSWIRE) -- IMUNON , Inc. (NASDAQ: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that it has filed a request for withdrawal with the Securities and Exchange Commission (SEC) of the Company's Registration Statement on Form S-1 (No. 333-286403), as amended, originally filed on April 4, 2025 (Registration Statement), as the Company no longer intends to pursue a public offering under the Registration Statement at this time. The Registration Statement has not been declared effective by the SEC, and no securities have been sold in connection with the …

Final data from the GAVRETO® (pralsetinib) Phase 1/2 ARROW study in RET fusion-positive NSCLC and other solid tumors Supportive data for REZLIDHIA® (olutasidenib) utilization in patients with mIDH1 R/R AML SOUTH SAN FRANCISCO, Calif. , May 22, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced seven upcoming poster presentations at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting and European Hematology Association (EHA) 2025 Congress.

SOUTH SAN FRANCISCO, Calif., May 22, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced the publication of two abstracts on the American Society of Clinical Oncology (ASCO) website in advance of the 2025 ASCO Annual Meeting, taking place May 30-June 3 in Chicago, Illinois.

BROOKINGS, S.D., May 22, 2025 (GLOBE NEWSWIRE) -- Daktronics, Inc. (Nasdaq: DAKT), a leading global designer and manufacturer of best-in-class dynamic video communication displays and control systems for customers worldwide today announced that Brad Wiemann, Interim Chief Executive Officer and Howard Atkins, Acting Chief Financial Officer will participate in the Craig-Hallum Capital Group's 22nd Annual Institutional Investor Conference to be held Wednesday, May 28th, 2025 in Minneapolis, MN.